Related Experiment Video

Updated: Aug 7, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Management of hepatitis C virus coinfection in HIV-infected persons

Jacqueline G O'Leary1, Raymond T Chung

  • 1Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

The AIDS Reader
|June 27, 2006
PubMed

Insights

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection accelerates liver disease. Pegylated interferon and ribavirin offer improved, though limited, sustained virologic response (SVR) in coinfected patients.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Approximately 300,000 individuals in the U.S. are coinfected with HIV and HCV.
  • HCV infection progresses more rapidly in coinfected patients, leading to significant liver disease.
  • Liver disease is a leading cause of mortality in HIV-infected patients due to advancements in antiretroviral therapy.

Purpose of the Study:

  • To evaluate the efficacy of pegylated interferon alfa plus ribavirin for treating HCV in HIV-HCV coinfected patients.
  • To assess sustained virologic response (SVR) rates in different HCV genotypes.
  • To identify early predictors of treatment success and consider drug interactions.

Main Methods:

  • Several clinical trials compared pegylated interferon alfa plus ribavirin with standard interferon plus ribavirin.
  • Treatment duration was 48 weeks for combination therapy.
  • Early virologic response was assessed at 12 weeks.

Main Results:

  • Pegylated interferon alfa plus ribavirin demonstrated superiority over standard interferon plus ribavirin.
  • SVR rates were 14%–29% for genotype 1 and 43%–73% for genotypes 2 and 3 HCV after 48 weeks.
  • Absence of early virologic response at 12 weeks predicted a low likelihood of achieving SVR.

Conclusions:

  • Aggressive management of HCV is crucial in coinfected patients.
  • Pegylated interferon alfa plus ribavirin is a superior treatment option, but SVR rates remain suboptimal for certain genotypes.
  • Early virologic response assessment can guide treatment duration, and potential drug interactions must be managed.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...